Hemophilia A

Introduction And Genetics

• X-linked recessive bleeding disorder.
• Results from decreased blood levels of functional procoagulant Factor VIII (FVIII).
• Incidence roughly 1 per 5000 males.
• Constitutes 80-85% of all hemophilia cases.
• F8 gene located near terminus of long arm of X chromosome.
• Spontaneous de novo mutations account for one-third of cases.
• Intron 22 inversion mutation identifiable in 45-50% of severe cases.
• Female carriers generally asymptomatic.
• Symptomatic female carriers occur secondary to skewed lyonization or Turner syndrome, exhibiting factor levels <40%.

Pathophysiology Of Hemorrhage

• Activated FVIII acts as essential cofactor.
• Participates in intrinsic tenase complex with activated Factor IX, calcium, and phospholipids on platelet surfaces.
• Complex drives sustained proteolytic activation of Factor X.
• FVIII deficiency yields insufficient thrombin generation.
• Normal platelet plug forms initially but lacks cross-linked fibrin stabilization.
• Results in delayed, ineffectual, highly friable clot formation.
• Rebleeding occurs with physiologic thrombolysis or minimal subsequent trauma.

Classification By Severity

Severity Phenotype	Factor Activity Level	Clinical Bleeding Characteristics	Proportion Of Cases
Severe	<1%	Frequent, spontaneous hemorrhage; spontaneous hemarthroses; deep soft tissue bleeds	70%
Moderate	1-5%	Gross bleeding post mild-to-moderate trauma; rare spontaneous bleeds	15%
Mild	5-40%	Severe hemorrhage only post moderate-to-severe trauma or surgery; often delayed diagnosis	15%

Clinical Manifestations

Neonatal Presentation

• FVIII does not cross placenta; bleeding symptoms possible at birth.
• Intracranial hemorrhage occurs in 1-4% of neonates, mostly birth trauma-related.
• Post-circumcision bleeding absent in 35% of severe and 70% of non-severe cases.
• Diagnosis frequently missed in newborn period without positive family history.

Post-Neonatal And Childhood Presentation

• Symptoms manifest when infant begins cruising or walking.
• Easy bruising, intramuscular hematomas, frequent joint bleeds.
• Prolonged bleeding from minor oral lacerations (torn frenulum).

Common Sites Of Hemorrhage

• Hemarthrosis: Hallmark manifestation. Ankles affected earliest, followed by knees and elbows.
• Target Joints: Recurrent bleeds into same joint induces synovial changes, precipitating further bleeds.
• Intramuscular Hematomas: High-risk locations include iliopsoas, calf, and forearm. Carry risk of compartment syndrome and nerve compression.
• Life-Threatening Hemorrhage: Intracranial, intraspinal, retropharyngeal, and retroperitoneal spaces. Exsanguination risk high without prompt factor replacement.
• Mucosal Bleeding: Epistaxis, dental extractions.

Diagnostic Evaluation

Screening Coagulation Assays

• Activated Partial Thromboplastin Time (aPTT): Markedly prolonged. Usually 2-3 times upper normal limit in severe disease. May remain normal in mild disease depending on reagent sensitivity.
• Prothrombin Time (PT): Normal.
• Platelet Count And Bleeding Time: Normal.
• Mixing Studies: aPTT corrects completely upon 1:1 mixing with normal pooled plasma, confirming factor deficiency rather than acquired inhibitor.

Confirmatory Assays

• Specific quantitative assay for FVIII activity required for definitive diagnosis.
• Expressed in International Units (IU); 1 IU equals factor amount in 1 mL normal plasma (100% activity).
• Neonatal FVIII levels artificially elevated secondary to acute-phase birth stress.
• Borderline low-normal levels in neonates necessitate repeat testing at 6 months of age.

Prenatal And Carrier Testing

• Chorionic villus sampling performed at 10-12 weeks gestation.
• Amniocentesis performed after 15 weeks gestation.
• Fetal blood sampling via cordocentesis feasible at 18-20 weeks.
• Carrier detection utilizes targeted mutation analysis.
• FVIII/vWF:Ag ratio <1.0 detects 80% of carriers with 95% accuracy.

Management Strategies

Principles Of Factor Replacement Therapy

• Intravenous replacement of deficient FVIII represents mainstay of therapy.
• Pharmacokinetics: 1 IU/kg raises plasma FVIII level by 2%. Half-life 8-12 hours.
• Dosing Formula: Dose (IU) = Desired Rise (%) × Body Weight (kg) × 0.5.

Factor Product Classes

• Plasma-Derived Concentrates: Undergo rigorous viral inactivation (solvent-detergent, pasteurization, nanofiltration).
• Recombinant Concentrates: Treatment of choice for previously untreated patients; eliminates bloodborne pathogen risk.
• Extended Half-Life (EHL) Products: FVIII protein fused to Fc portion of IgG1 or PEGylated. Reduces clearance; facilitates less frequent prophylactic dosing (every 3-5 days).

Acute Hemorrhage Management (On-Demand Therapy)

Hemorrhage Type	Target FVIII Level	Recommended FVIII Dosing	Adjunct Interventions
Hemarthrosis	30-50%	50-60 IU/kg day 1; 20 IU/kg every other day	Rest, cold compress, immobilization.
Intramuscular	40-50%	50 IU/kg initially; 20 IU/kg every other day	Monitor for compartment syndrome.
Oral/Dental	50%	20 IU/kg single dose	Antifibrinolytics critical.
Life-Threatening/CNS	100%	50-75 IU/kg bolus; maintain trough >50% for 5-7 days	Hospitalization; immediate infusion prior to imaging.

Prophylaxis Therapy

• Standard of care for children with severe hemophilia A.
• Objective: Convert severe phenotype to moderate phenotype.
• Maintains trough factor levels >1-2%.
• Prevents spontaneous hemorrhages; preserves joint integrity.
• Standard Regimens: Intravenous administration 3-4 times weekly for standard products. Frequency reduced with extended half-life products.
• Often requires surgical insertion of central venous access devices in young children; carries inherent infection and thrombosis risks.

Novel Non-Factor And Gene Therapies

• Emicizumab: Bispecific humanized monoclonal antibody bridging FIXa and FXa. Mimics FVIIIa cofactor activity. Administered subcutaneously weekly to monthly. Highly effective for routine prophylaxis regardless of inhibitor status. Shortens aPTT artificially.
• Efanesoctocog Alfa: Modified extended half-life recombinant FVIII decoupled from endogenous von Willebrand factor.
• Fitusiran: Small interfering RNA molecule inhibiting antithrombin synthesis. Rebalances hemostasis.
• Gene Therapy (Valoctocogene Roxaparvovec): Utilizes adeno-associated viral (AAV) vectors to deliver FVIII gene. Restores endogenous factor production.

Ancillary Therapies

• Desmopressin (DDAVP): Stimulates endogenous endothelial release of FVIII and vWF. Increases baseline FVIII twofold to fivefold. Indicated for mild hemophilia A. Dose: 0.3 μg/kg intravenously or 150-300 μg intranasal spray (Stimate). Contraindicated in children <2 years due to severe hyponatremic seizure risk. Tachyphylaxis occurs after 4-5 consecutive days.
• Antifibrinolytic Agents: Epsilon-aminocaproic acid (EACA) or tranexamic acid. Inhibit plasminogen activation. Efficacious for mucosal, oral, and epistaxis hemorrhage. Contraindicated in urinary tract hemorrhage due to intrarenal clot formation risk.

Complications

Inhibitor Development

• Represents most severe complication of modern replacement therapy.
• Neutralizing IgG alloantibodies target exogenous FVIII.
• Occurs in 20-30% of severe Hemophilia A patients.
• Risk factors: Large gene deletions, African-American ethnicity, early intensive factor exposure (trauma, surgery).
• Quantification: Bethesda Assay. 1 Bethesda Unit (BU) neutralizes 1 IU/mL of factor activity.

Management Of Inhibitors

• Low Responders (<5 BU): Exhibit no anamnestic titer rise upon rechallenge. Managed with high-dose specific FVIII concentrates to overwhelm circulating inhibitor.
• High Responders (>5 BU): Exhibit rapid anamnestic response. Require bypassing agents for hemostatic control.
  • Activated Prothrombin Complex Concentrate (aPCC / FEIBA): Contains FVIIa, FXa, prothrombin. Dose: 75-100 U/kg q8-12h. Thrombogenic risk at high/prolonged doses.
  • Recombinant FVIIa (NovoSeven): Bypasses FVIII requirement. Dose: 90 μg/kg q2h.
• Immune Tolerance Induction (ITI): Frequent, high-dose administration of FVIII concentrate (e.g., 200 IU/kg/day). Aims to induce immunologic tolerance and eradicate inhibitor. Success rate approximately 70% in Hemophilia A.
• Immunosuppression: Rituximab (anti-CD20 antibody) utilized in ITI failure.
• Plasmapheresis: Extracorporeal immunoadsorption rapidly reduces severe acute inhibitor titers in life-threatening bleeding situations.

Hemophilic Arthropathy

• Chronic, debilitating joint destruction stemming from recurrent hemarthroses.
• Intra-articular hemorrhage triggers macrophage proliferation via heme iron.
• Synovial inflammation ensues.
• Synovium thickens, develops frond-like projections susceptible to mechanical pinching and recurrent bleeding (target joint cycle).
• Culminates in articular cartilage erosion, raw bone exposure, and eventual joint fusion.

Transfusion-Transmitted Infections

• Historically high transmission rates of Hepatitis B, Hepatitis C, and HIV via non-inactivated plasma products.
• Modern risk virtually eliminated via stringent donor nucleic acid testing, solvent-detergent viral inactivation, nanofiltration, and widespread utilization of recombinant factors.